BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 33914324)

  • 1. Prognosis of the patients suffered from uterine carcinosarcoma from rural and urban areas.
    Danska-Bidzinska A; Nasierowska-Guttmejer A; Bakula-Zalewska E; Bidzinski M; Wierzba W
    Ginekol Pol; 2021; 92(11):774-777. PubMed ID: 33914324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Impact of Adjuvant Therapy on Survival and Recurrence Patterns in Women With Early-Stage Uterine Carcinosarcoma: A Multi-institutional Study.
    Guttmann DM; Li H; Sevak P; Grover S; Jacobson G; Feldman A; Rubin S; Chu C; Bhatia S; Elshaikh MA; Lin LL
    Int J Gynecol Cancer; 2016 Jan; 26(1):141-8. PubMed ID: 26509850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaginal brachytherapy for early-stage carcinosarcoma of the uterus.
    Brown LC; Petersen IA; Haddock MG; Bakkum-Gamez JN; Lee LJ; Cimbak NC; Berkowitz RS; Viswanathan AN
    Brachytherapy; 2015; 14(4):433-9. PubMed ID: 25890795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stage I uterine carcinosarcoma: Matched cohort analyses for lymphadenectomy, chemotherapy, and brachytherapy.
    Seagle BL; Kanis M; Kocherginsky M; Strauss JB; Shahabi S
    Gynecol Oncol; 2017 Apr; 145(1):71-77. PubMed ID: 28317560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of combination cisplatin and ifosfamide chemotherapy with vaginal cuff brachytherapy in the first line treatment of uterine carcinosarcoma.
    Abu-Khalaf MM; Raza MA; Hatzis C; Wang H; Lin K; Higgins S; Ratner E; Silasi DA; Azodi M; Rutherford TJ; Santin AD; Schwartz PE
    Eur J Gynaecol Oncol; 2016; 37(2):199-203. PubMed ID: 27172745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of adjuvant therapy on recurrence patterns in stage I uterine carcinosarcoma.
    Matsuo K; Omatsu K; Ross MS; Johnson MS; Yunokawa M; Klobocista MM; Im DD; Bush SH; Ueda Y; Takano T; Blake EA; Hasegawa K; Baba T; Shida M; Satoh S; Yokoyama T; Machida H; Adachi S; Ikeda Y; Iwasaki K; Miyake TM; Yanai S; Nishimura M; Nagano T; Takekuma M; Takeuchi S; Pejovic T; Shahzad MM; Ueland FR; Kelley JL; Roman LD
    Gynecol Oncol; 2017 Apr; 145(1):78-87. PubMed ID: 28215838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination external beam radiotherapy and high-dose-rate intracavitary brachytherapy for uterine cervical cancer: analysis of dose and fractionation schedule.
    Toita T; Kakinohana Y; Ogawa K; Adachi G; Moromizato H; Nagai Y; Maehama T; Sakumoto K; Kanazawa K; Murayama S
    Int J Radiat Oncol Biol Phys; 2003 Aug; 56(5):1344-53. PubMed ID: 12873679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of adjuvant pelvic radiation "sandwiched" between ifosfamide or ifosfamide plus cisplatin in women with uterine carcinosarcoma.
    Einstein MH; Klobocista M; Hou JY; Lee S; Mutyala S; Mehta K; Reimers LL; Kuo DY; Huang GS; Goldberg GL
    Gynecol Oncol; 2012 Jan; 124(1):26-30. PubMed ID: 22055846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multimodality adjuvant therapy and survival outcomes in stage I-IV uterine carcinosarcoma.
    McEachron J; Heyman T; Shanahan L; Tran V; Friedman M; Gorelick C; Economos K; Singhal PK; Lee YC; Kanis MJ
    Int J Gynecol Cancer; 2020 Jul; 30(7):1012-1017. PubMed ID: 32447295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors impacting survival in early stage uterine carcinosarcoma.
    Kurnit KC; Previs RA; Soliman PT; Westin SN; Klopp AH; Fellman BM; Lu KH; Ramondetta LM; Fleming ND
    Gynecol Oncol; 2019 Jan; 152(1):31-37. PubMed ID: 30414738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Postoperative radiotherapy of uterine sarcoma: a multicentric retrospective study].
    Champetier C; Hannoun-Levi JM; Resbeut M; Azria D; Salem N; Tessier E; Ellis S; Cowen D;
    Cancer Radiother; 2011 Apr; 15(2):89-96. PubMed ID: 20674447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paclitaxel and carboplatin in patients with completely or optimally resected carcinosarcoma of the uterus: a phase II trial by the Japanese Uterine Sarcoma Group and the Tohoku Gynecologic Cancer Unit.
    Otsuki A; Watanabe Y; Nomura H; Futagami M; Yokoyama Y; Shibata K; Kamoi S; Arakawa A; Nishiyama H; Katsuta T; Kudaka W; Shimada M; Sato N; Kotera K; Katabuchi H; Yaegashi N
    Int J Gynecol Cancer; 2015 Jan; 25(1):92-7. PubMed ID: 25347097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review of Recommended Treatment of Uterine Carcinosarcoma.
    Menczer J
    Curr Treat Options Oncol; 2015 Nov; 16(11):53. PubMed ID: 26374341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Uterine adenosarcoma with sarcomatous overgrowth versus uterine carcinosarcoma: comparison of treatment and survival.
    Krivak TC; Seidman JD; McBroom JW; MacKoul PJ; Aye LM; Rose GS
    Gynecol Oncol; 2001 Oct; 83(1):89-94. PubMed ID: 11585418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of brachytherapy and external beam radiation therapy for early stage, node-negative uterine carcinosarcoma.
    Patel N; Hegarty SE; Cantrell LA; Mishra MV; Showalter TN
    Brachytherapy; 2015; 14(5):606-12. PubMed ID: 26166579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multi-institutional study of outcomes in stage I-III uterine carcinosarcoma.
    Dickson EL; Vogel RI; Gehrig PA; Pierce S; Havrilesky L; Secord AA; Dottino J; Fader AN; Ricci S; Geller MA
    Gynecol Oncol; 2015 Nov; 139(2):275-82. PubMed ID: 26348313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pulsed low dose rate brachytherapy for uterine cervix carcinoma.
    Rogers CL; Freel JH; Speiser BL
    Int J Radiat Oncol Biol Phys; 1999 Jan; 43(1):95-100. PubMed ID: 9989519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors and adjuvant therapy in uterine carcinosarcoma.
    Wu TI; Hsu KH; Huang HJ; Hsueh S; Chou HH; Tsai CS; Ho KC; Chao A; Chang TC; Lai CH
    Eur J Gynaecol Oncol; 2008; 29(5):483-8. PubMed ID: 19051818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical analysis of 12 cases of uterine carcinosarcoma].
    Wang LH; Xiong Y; Li YF; Li JD; Feng YL; Li YJ; Chen C; Chen L
    Ai Zheng; 2008 May; 27(5):516-9. PubMed ID: 18479602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two fractions of high-dose-rate brachytherapy in the management of cervix cancer: clinical experience with and without chemotherapy.
    Sood BM; Gorla G; Gupta S; Garg M; Deore S; Runowicz CD; Fields AL; Goldberg GL; Anderson PS; Vikram B
    Int J Radiat Oncol Biol Phys; 2002 Jul; 53(3):702-6. PubMed ID: 12062615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.